EIKN
NASDAQEikon Therapeutics Inc.
$9.67-1.02 (-9.54%)
News25/Ratings6
Price$9.67-1.11 (-10.30%)
01:30 PM07:45 PM
News · 26 weeks27-75%
2025-10-262026-04-19
Mix2790d
- Insider13(48%)
- Analyst6(22%)
- SEC Filings4(15%)
- Other3(11%)
- Offering1(4%)
Latest news
25 items- SECEikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate UpdatesClosed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates. "2025 was an important year of progress for Eikon's business and clinical programs," said Roger M. Perlmutter, M.D., Ph.D., Chief Execut
- SECSEC Form 10-K filed by Eikon Therapeutics Inc.10-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Klobuchar Michael A4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Director Huffines Robert Luther4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Director Frazier Kenneth C4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Officer Perlmutter Roger M4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Officer Thorner Benjamin Bruno4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Baynes Roy D.4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Bowie Alfred Lloyd Jr.4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Eikon TherapeuticsCantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight
- ANALYSTMorgan Stanley initiated coverage on Eikon Therapeutics with a new price targetMorgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00
- ANALYSTAnalyst initiated coverage on Eikon Therapeutics with a new price targetAnalyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00
- ANALYSTMizuho initiated coverage on Eikon Therapeutics with a new price targetMizuho initiated coverage of Eikon Therapeutics with a rating of Outperform and set a new price target of $26.00
- ANALYSTBofA Securities initiated coverage on Eikon Therapeutics with a new price targetBofA Securities initiated coverage of Eikon Therapeutics with a rating of Buy and set a new price target of $34.00
- ANALYSTWedbush initiated coverage on Eikon Therapeutics with a new price targetWedbush initiated coverage of Eikon Therapeutics with a rating of Underperform and set a new price target of $7.00
- SECSEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
- SECSEC Form SCHEDULE 13D filed by Eikon Therapeutics Inc.SCHEDULE 13D - Eikon Therapeutics, Inc. (0001861123) (Subject)
- SECSEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
- INSIDEROfficer Perlmutter Roger M converted options into 284,857 shares (SEC Form 4)4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERLarge owner Column Group Iv Gp, Lp converted options into 3,595,340 shares and bought $38,119,680 worth of shares (2,117,760 units at $18.00) (SEC Form 4)4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERLarge owner Foresite Capital Management Iv, Llc converted options into 4,041,687 shares and bought $999,990 worth of shares (55,555 units at $18.00) (SEC Form 4)4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERDirector Frazier Kenneth C bought $1,999,998 worth of shares (111,111 units at $18.00) (SEC Form 4)4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERDirector Wolfe Josh bought $4,999,968 worth of shares (277,776 units at $18.00) and converted options into 5,695,010 shares (SEC Form 4)4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERLarge owner Lux Venture Partners V, Llc bought $4,999,968 worth of shares (277,776 units at $18.00) and converted options into 5,695,010 shares (SEC Form 4)4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)